{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:58:34Z","timestamp":1772665114775,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"The Wellcome Trust","doi-asserted-by":"publisher","award":["087540"],"award-info":[{"award-number":["087540"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.024","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T08:14:59Z","timestamp":1542442499000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Interferon gamma (IFN-\u03b3) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens"],"prefix":"10.1016","volume":"37","author":[{"given":"Ritah","family":"Nakiboneka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Mugaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty O.","family":"Auma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kintu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Lindan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Bridget","family":"Nanteza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Serwanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.024_b0005","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1084\/jem.20090365","article-title":"The first T-cell response to transmitted\/founder virus contributes to the control of acute viremia in HIV-1 infection","volume":"206","author":"Goonetilleke","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.024_b0010","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.189.6.991","article-title":"Dramatic rise in plasma viremia after CD8(+) T-cell depletion in simian immunodeficiency virus-infected macaques","volume":"189","author":"Jin","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.024_b0015","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1128\/JVI.77.13.7330-7340.2003","article-title":"Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences","volume":"77","author":"Altfeld","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0020","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.11.024_b0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2006.11.010","article-title":"A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses","volume":"320","author":"Boulet","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.11.024_b0030","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1128\/JVI.00182-09","article-title":"Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T-cells","volume":"83","author":"Streeck","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030403","article-title":"HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T-cell response against HIV-1","volume":"3","author":"Altfeld","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.11.024_b0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/aid.2006.0114","article-title":"Evaluation of cellular immune responses in subjects chronically infected with HIV type 1","volume":"23","author":"Fu","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2018.11.024_b0045","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1172\/JCI58653","article-title":"A high-throughput single-cell analysis of human CD8(+) T-cell functions reveals discordance for cytokine secretion and cytolysis","volume":"121","author":"Varadarajan","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.11.024_b0050","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.176.3.739","article-title":"Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells","volume":"176","author":"Biswas","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.024_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/35065118","article-title":"Skewed maturation of memory HIV-specific CD8 T lymphocytes","volume":"410","author":"Champagne","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.11.024_b0060","first-page":"247","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat RevImmunol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0065","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.4049\/jimmunol.0803801","article-title":"Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point","volume":"182","author":"Burgers","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0070","doi-asserted-by":"crossref","first-page":"e104235","DOI":"10.1371\/journal.pone.0104235","article-title":"Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression","volume":"9","author":"Ghiglione","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.11.024_b0075","doi-asserted-by":"crossref","first-page":"e1000917","DOI":"10.1371\/journal.ppat.1000917","article-title":"Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control","volume":"6","author":"Hersperger","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.11.024_b0080","doi-asserted-by":"crossref","first-page":"13812","DOI":"10.1073\/pnas.240469997","article-title":"Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T-cells are associated with asymptomatic HIV-1 infection","volume":"97","author":"Cocchi","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.11.024_b0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2249.1992.tb05823.x","article-title":"Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI)","volume":"90","author":"Bell","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00063030-199810030-00005","article-title":"Use of interleukin-2 in immunotherapy of human immunodeficiency virus infection","volume":"10","author":"Reier","year":"1998","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2018.11.024_b0095","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.15.5.2359","article-title":"Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA","volume":"15","author":"Talley","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0100","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/cyto.a.22510","article-title":"NetFCM: a semi-automated web-based method for flow cytometry data analysis","volume":"85","author":"Frederiksen","year":"2014","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2018.11.024_b0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/QAD.0b013e328342ff93","article-title":"Global trends in molecular epidemiology of HIV-1 during 2000\u20132007","volume":"25","author":"Hemelaar","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2018.11.024_b0110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4269\/ajtmh.2005.73.1.0730044","article-title":"Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion","volume":"73","author":"Al-Sherbiny","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.11.024_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0b013e32835ac0e1","article-title":"Poor HIV control in HLA-B*27 and B*57\/58 noncontrollers is associated with limited number of polyfunctional Gag p24-specific CD8+ T-cells","volume":"27","author":"Techakriengkrai","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2018.11.024_b0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/01.aids.0000176216.02743.98","article-title":"HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T-cell responses compared with consensus subtypes B and M group 15-mer peptides","volume":"19","author":"Rutebemberwa","year":"2005","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2018.11.024_b0125","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1016\/j.vaccine.2014.05.021","article-title":"Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides","volume":"32","author":"Mugaba","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.024_b0130","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2011.0175","article-title":"Profile of T-cell recognition of HIV Type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected ugandan population","volume":"28","author":"Serwanga","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2018.11.024_b0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2018.11.024_b0145","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/JVI.01707-10","article-title":"Epitope mapping of HIV-specific CD8+ T-cell responses by multiple immunological readouts reveals distinct specificities defined by function","volume":"85","author":"Richmond","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0150","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.vaccine.2017.02.038","article-title":"Cryopreservation-related loss of antigen-specific IFNgamma producing CD4(+) T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy","volume":"35","author":"Ford","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.024_b0155","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1086\/424490","article-title":"Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T-cells","volume":"190","author":"Horton","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.024_b0160","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1182\/blood.V96.9.3094","article-title":"Impaired function of circulating HIV-specific CD8(+) T-cells in chronic human immunodeficiency virus infection","volume":"96","author":"Shankar","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.11.024_b0165","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood.V99.7.2505","article-title":"Persistent numbers of tetramer+ CD8(+) T-cells, but loss of interferon-gamma+ HIV-specific T-cells during progression to AIDS","volume":"99","author":"Kostense","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.11.024_b0170","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/JVI.02968-13","article-title":"Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T-cell responses on HIV set point","volume":"88","author":"Riou","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/aid.2015.0157","article-title":"Macrophage inflammatory protein-1 beta and interferon gamma responses in ugandans with HIV-1 acute\/early infections","volume":"32","author":"Obuku","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2018.11.024_b0180","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.4049\/jimmunol.0803945","article-title":"Rapid up-regulation and granule-independent transport of perforin to the immunological synapse define a novel mechanism of antigen-specific CD8+ T-cell cytotoxic activity","volume":"182","author":"Makedonas","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0185","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.11.024_b0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/eji.200737768","article-title":"Polyfunctional T-cell responses are a hallmark of HIV-2 infection","volume":"38","author":"Duvall","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0195","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.1073\/pnas.1202143109","article-title":"Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection","volume":"109","author":"Fang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.11.024_b0200","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1128\/JVI.00138-10","article-title":"Phenotypic and functional profile of HIV-inhibitory CD8 T-cells elicited by natural infection and heterologous prime\/boost vaccination","volume":"84","author":"Freel","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.024_b0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/cells1020111","article-title":"ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials","volume":"1","author":"Malyguine","year":"2012","journal-title":"Cells"},{"key":"10.1016\/j.vaccine.2018.11.024_b0210","doi-asserted-by":"crossref","first-page":"e1000798","DOI":"10.1371\/journal.ppat.1000798","article-title":"Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T-cells","volume":"6","author":"Makedonas","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.11.024_b0215","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1128\/JVI.02565-09","article-title":"Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T-cells defined by interleukin-7R{alpha} (CD127) and perforin expression","volume":"84","author":"Cellerai","year":"2010","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18315470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T04:41:48Z","timestamp":1572756108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18315470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18315470"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon gamma (IFN-\u03b3) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}